Researchers from West Orange, N.J.-based RWJBarnabas Health, New Brunswick, N.J.-based Rutgers Cancer Institute, Boston-based Tufts Medical Center and the University of Manchester in England, have developed a risk prediction model for early-stage classic Hodgkin lymphoma.
The model is called the Early-stage Hodgkin International Prognostication Index and predicts a patient’s two-year progression-free survival, according to a June 19 news release from RWJBarnabas Health.
The organizations developed and validated the model using clinical trial data from more than 3,000 adult early-stage Hodgkin lymphoma patients across four international phase 3 trials and two real-world registry cohorts of more than 2,300 early-stage classic Hodgkin lymphoma patients.
The model uses common clinical data such as sex, tumor size, and hemoglobin and albumin levels to predict a patient’s chance of two-year survival.
The model’s development and validation data was published June 19 in NEJM Evidence.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
